Mar 15, 2023 / 05:20PM GMT
Leland James Gershell - Oppenheimer & Co. Inc., Research Division - MD & Senior Analyst
Thank you, and good afternoon, everyone. Welcome back to another session here at the third day of Oppenheimer's 33rd Annual Healthcare Conference. I'm Leland Gershell, one of the analysts on the biotech equity research team here at Oppenheimer, and we're very delighted to have with us Alnylam Pharmaceuticals, will be having a fireside chat with Akshay Vaishnaw, who's the President of Alnylam.
We do cover Alnylam stock with an outperform rating. And we will have about half an hour to have a good discussion. If you do have any questions, feel free to send those over. I will see if I can work those in. But I think we're pretty good in terms of our road map for this. So Akshay, thank you very much, and welcome to the chat.
Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. - President
Leland, thanks so much for inviting me. And it's my pleasure.
Alnylam Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers